COPENHAGEN--(BUSINESS WIRE)-- Symphogen announced today that Phase 2 data will be presented from an open-label, multi-center clinical trial evaluating the safety and tolerability of rozrolimupab (SYM001) in adult, RhD positive, non-splenectomized patients with Immune thrombocytopenia (ITP) at the 16th Congress of the European Hematology Association meeting (http://eha.eurocongres.com/16th/) in London, UK on June 10 from 5:45 to 7:00 PM. Preliminary results will be presented in a poster entitled “Phase II results of the first-in-class anti-RhD antibody mixture, rozrolimupab in primary immune thrombocytopenia (ITP)” by professor Tadeusz Robak of University of Lodz, Poland at the Immune Thrombocytopenia Poster Session.
About Rozrolimupab (SYM001)
Rozrolimupab is a fully human anti-RhD monoclonal antibody (mAb) mixture, comprised of 25 mAbs binding to RhD. Rozrolimupab is produced by a single-batch manufacturing strategy, designed to capture the natural diversity of the human antibody response to RhD as a modern counterpart to the plasma-derived anti-RhD immunoglobulins currently used in the treatment of ITP.
Symphogen develops antibody therapeutics (mixtures of monoclonal antibodies) to help people with serious diseases and significant unmet medical needs. With its proprietary, unique Symplex™ discovery, SymSelect™ lead selection and Sympress™ manufacturing platforms, the company captures the diversity and specificity of the natural immune response in rationally designed recombinant antibody compositions. Symphogen is maturing a diversified pipeline of internal and partnered products across multiple indications including cancer, autoimmune and infectious disease. Symphogen is a private biopharmaceutical company headquartered in Copenhagen, Denmark. For more information, please visit www.symphogen.com.
KEYWORDS: United Kingdom Europe Denmark
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Oncology Pharmaceutical